Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

April 29

2021

Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

March 15

2021

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

December 2

2020

Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department

October 19

2020

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

September 14

2020

US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients

September 8

2020

Dr David Buckeridge Joins Cycle Group Holdings’ Board of Directors

September 8

2020

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

September 5

2020

Cycle Pharmaceuticals Secures $25 Million Debt Financing

August 5

2020

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

May 13

2020

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

May 5

2020

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

April 19

2020

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

March 13

2020

Cycle Pharmaceuticals’ Supply Chain update

December 18

2019

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

November 18

2019

Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph

October 31

2019

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

April 28

2019

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

November 22

2018

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

November 19

2018

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

November 12

2018

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

August 29

2018

Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.

August 29

2018

Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.

November 10

2017

Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs

August 1

2017

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1

June 2

2017

First recommendation for HT-1 treatment in Quebec by INESSS

December 19

2016

CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

November 8

2016

CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1

FOLLOW US
ABOUT US
TECHNOLOGY PARTNERSHIPS